Rgenix is a privately-held clinical-stage biopharmaceutical company developing first-in-class drugs that target key pathways in cancer progression.

310 E 67th St, Suite 1-12‎ New York, NY
(646) 856-9261
info@rgenix.com

Management

Masoud Tavazoie, M.D., Ph.D.
Chief Executive Officer & Co-founder

Masoud is co-founder, Board Director, and the Chief Executive Officer of Rgenix.

David Darst
David Darst, M.B.A.
CHIEF OPERATING OFFICER

David co-leads Rgenix’s financing, corporate development, and drug development efforts.

Roger Waltzman
Roger Waltzman, M.D., M.B.A.
Chief Medical Officer

Roger is a Board-certified Medical Oncologist with over 20 years of experience.

Stephen Wald, MS
Stephen Wald
VP of Chemistry & Pharmaceutical Sciences

Steve is responsible for chemical, analytical and formulation development, and manufacturing scale-up, of Rgenix’s drug candidates.

Isabel Kurth
Isabel Kurth, Ph.D.
VP of Research

Isabel has authored numerous book chapters and international reviews, and her research discoveries were published in leading journals.

Foster Gonsalves
Foster Gonsalves, Ph.D., M.P.H.
VP of Drug Development & Strategy

Foster heads preclinical development at Rgenix. Prior to joining Rgenix, Foster was a management consultant within the life sciences practice

Corey Sohmer
Corey Sohmer, M.B.A.
VP of Finance & Accounting

Corey brings to Rgenix more than 25 years of progressive leadership experience in finance and accounting.

Michael Szarek
Michael Szarek, Ph.D.
VP of Clinical & Regulatory Affairs

Michael leads clinical and regulatory affairs at Rgenix.